Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) has been assigned an average rating of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong […]

Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) has earned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating […]